Download my slides for “Complementary and Alternative Medicine in IBD” here:
U of Michigan’s Patient-2-Patient Education Project 2021
Bookmark the permalink.
Twitter
The delta of 33% for clinical remission by CDAI is pretty impressive, especially with a lot of bio-experienced patients. Larger than IFX in the bionaive era in ACCENT. https://twitter.com/mchiorean4/status/1524768083285405697
Upadacitinib (selective JAK1-inhibitor) achieved all clinical & endoscopic endpoints for maintenance in #CrohnsDisease in the phase 3 program. Number needed to treat of 3 for clinical and 4 for endoscopic endpoints. Great news for our #IBD patients https://news.abbvie.com/news/press-releases/upadacitinib-rinvoq-achieved-clinical-remission-and-endoscopic-response-at-one-year-in-phase-3-maintenance-study-in-patients-with-crohns-disease.htm?view_id=2421
